Jung Yong Hong
Overview
Explore the profile of Jung Yong Hong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
146
Citations
1431
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Whi W, Lee H, Hong J, Kang W, Cho Y, Moon S, et al.
Anticancer Res
. 2025 Mar;
45(3):1273-1280.
PMID: 40037882
Background/aim: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, and treatment outcomes for advanced disease remain suboptimal. Immunotherapy, particularly atezolizumab plus bevacizumab, has shown promise in improving...
2.
Shin M, Choi D, Jung J, Kim D, Lim S, Kim S, et al.
Cancer Res Treat
. 2025 Feb;
PMID: 39999774
Purpose: The epidermal growth factor receptor (EGFR) is a therapeutic target with confirmed clinical efficacy for several cancer types. We aimed to identify EGFR aberrations and their associations with other...
3.
Park J, Hong J, Han K, Shen J, Park S
Cancer Res Treat
. 2025 Feb;
PMID: 39901700
Purpose: Previous studies suggested an association between alcohol consumption and reduced kidney cancer risk. Given a potential interaction between alcohol's insulin-sensitizing effect and hyperglycemia-related insulin resistance, we aimed to assess...
4.
Kim R, Park J, Kwon M, An M, Hong J, Park J, et al.
Oncol Res
. 2024 Dec;
33(1):57-65.
PMID: 39735665
Background: Immune checkpoint inhibitors (ICIs) are effective in a subset of patients with metastatic solid tumors. However, the patients who would benefit most from ICIs in biliary tract cancer (BTC)...
5.
Min J, Yu J, Kim S, Kim Y, Kim K, Park H, et al.
J Cachexia Sarcopenia Muscle
. 2024 Nov;
16(1):e16343.
PMID: 39578950
Background: Patients with borderline resectable (BR) or locally advanced pancreatic cancer (LAPC) require complex management strategies. This study evaluated the prognostic significance of the perichemotherapy skeletal muscle index (SMI) and...
6.
Park J, Hong J, Han K, Park Y, Park J, Lim H, et al.
Eur J Cancer
. 2024 Oct;
213:114312.
PMID: 39447448
Background & Aims: Hyperglycemia is associated with an increased risk of gallbladder cancer (GBC), potentially by inhibiting gallbladder motility and inducing prolonged cholestasis. Although intermediate hyperglycemia (or prediabetes) is highly...
7.
Kim M, Kim Y, Suh K, Kim S, Kim J, Jeong J, et al.
Cancer
. 2024 Oct;
131(1):e35609.
PMID: 39422602
Background: In this single-arm, multicenter, phase 2 trial, the authors evaluated the efficacy and safety of avelumab plus gemcitabine in patients with leiomyosarcoma (LMS) who failed on first-line chemotherapy. Methods:...
8.
Park B, Choi M, Ryu K, Park C, Choi M, Yoon S, et al.
Exp Cell Res
. 2024 Sep;
442(2):114248.
PMID: 39260673
Ibrutinib, a Bruton Tyrosine Kinase (BTK) inhibitor, has shown effectiveness against various B-cell lymphoid malignancies. However, prolonged usage can induce resistance, affecting treatment outcomes. The oncogenic microRNA, miR-155-5p, is associated...
9.
Lim S, Lee S, Hong J, Lee J, Kim S
Transl Cancer Res
. 2024 Aug;
13(7):3695-3703.
PMID: 39145064
Background: In v-raf murine sarcoma viral oncogene homolog B1 (BRAF)-mutant colorectal cancer (CRC), encorafenib-cetuximab has been established as standard second-line therapy, but not all patients respond and the duration of...
10.
Choi D, Jang H, Lim S, Kim S, Hong J, Park S, et al.
Pathol Res Pract
. 2024 Aug;
261:155473.
PMID: 39106591
Background: The Kirsten rat sarcoma virus (KRAS) is a prominent proto-oncogene. Several treatments for KRAS mutations have been developed. However, KRAS amplification, a KRAS alteration, is poorly understood, and there...